EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtOpen Access · CC BY 4.0

Newborn Screening for Metachromatic Leukodystrophy: A Systematic Literature Review

Lucia Laugwitz iD, Andrew Shenker, Erica F Sluys, Stéphane Pintat iD, David Whiteman iD, Charlotte Chanson

International Journal of Neonatal Screening · 05.11.2025 · 11 (4) · 103

DOI: 10.3390/ijns11040103 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Neonatal Screening, online erschienen am 05.11.2025. Verfasst von Lucia Laugwitz und 5 weiteren Autor:innen. Beteiligte Einrichtung: Neuropaediatrics, General Paediatrics, Diabetology, Endocrinology and Social Paediatrics, University Hospital Tübingen, University of Tübingen, 72076…. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Orchard Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A systematic literature review was conducted to evaluate the emerging evidence on newborn screening (NBS) for metachromatic leukodystrophy (MLD; MIM #250100). The review focuses on (1) screening assay performance, (2) diagnostic confirmation methods and care pathways, (3) feasibility of population-based identification, and (4) the impact of early diagnosis and treatment on health outcomes. Electronic databases were searched in February 2025, and supplementary searches were performed up to 17 June 2025, for articles referencing NBS for MLD and treatments for MLD; 52 publications were eligible for inclusion. Nationwide NBS for MLD is currently carried out in Norway and large prospective pilots are running in Germany, Austria, Italy and the US. MLD meets established Wilson and Jungner criteria, with a reliable screening algorithm, established confirmatory diagnostics, and actionable care pathways. There is ongoing work to develop tools to predict disease severity and subtype. Early intervention—via gene therapy for early-onset MLD and hematopoietic stem cell transplantation (HSCT) for late-onset forms—significantly improves outcomes when initiated before symptom onset. This review provides the first comprehensive synthesis of the evidence supporting MLD for inclusion in NBS programs, underscoring the public health value of early identification and intervention.

Schlagwörter

Stichwörter der Autor:innen

metachromatic leukodystrophynewborn screeningsystematic literature review

Autor:innen und Institutionen

  • Neuropaediatrics, General Paediatrics, Diabetology, Endocrinology and Social Paediatrics, University Hospital Tübingen, University of Tübingen, 72076 Tübingen, Germany.
  • Independent Clinical Consultant, Pennington, NJ 08534, USA.
  • And You SARL, 1260 Nyon, Switzerland.
  • Oxford PharmaGenesis, Oxford OX13 5QJ, UK.
  • Independent Clinical Consultant, Cape Elizabeth, ME 04107, USA.
  • Orchard Therapeutics, London W6 8PW, UK.

ORCID-Profile: Lucia Laugwitz, Stéphane Pintat, David Whiteman

Förderung

  • Orchard Therapeutics

Zitieren

APA

Laugwitz, L., Shenker, A., Sluys, E. F., Pintat, S., Whiteman, D., & Chanson, C. (2025). Newborn Screening for Metachromatic Leukodystrophy: A Systematic Literature Review. International Journal of Neonatal Screening, 11(4), 103. https://doi.org/10.3390/ijns11040103

Vancouver

Laugwitz L, Shenker A, Sluys EF, Pintat S, Whiteman D, Chanson C. Newborn Screening for Metachromatic Leukodystrophy: A Systematic Literature Review. International Journal of Neonatal Screening. 2025;11(4):103. doi:10.3390/ijns11040103

BibTeX
@article{Laugwitz2025,
  author = {Laugwitz, Lucia and Shenker, Andrew and Sluys, Erica F and Pintat, Stéphane and Whiteman, David and Chanson, Charlotte},
  title = {Newborn Screening for Metachromatic Leukodystrophy: A Systematic Literature Review},
  journal = {International Journal of Neonatal Screening},
  year = {2025},
  volume = {11},
  number = {4},
  pages = {103},
  doi = {10.3390/ijns11040103}
}
Kostenlos starten →